8:00 - 8:30 BST
virtual

Fireside Chat with Marcus Schindler & John Carroll

Marcus Schindler

Marcus Schindler

Executive Vice President for Research & Early Development and CSO

Novo Nordisk

John Carroll

John Carroll

Founder & Editor

Endpoints News

9:00 - 9:55 BST
virtual
sponsored by
Novotech

Building a better CAR

The first generation of CAR-Ts helped revolutionize the treatment of liquid cancers, offering some jaw-dropping data and presenting big challenges in manufacturing and delivery. Now a new generation of cell therapies is taking shape in the clinic that promise to not only be easier to manufacture, but could also break down barriers on exhaustion, durability and more. We’ll talk with the transatlantic pioneers who are moving this field forward.

sponsored by
Novotech
Alain Maiore

Alain Maiore

Co-Founder & Chief Operating Officer

Mnemo Therapeutics

Joanna Brewer

Joanna Brewer

Chief Scientific Officer

Adaptimmune

Rob Igarashi

Rob Igarashi

Head of Discovery & Pre-Clinical Development in Global Oncology Research

Sanofi

Eric Vivier

Eric Vivier

Chief Scientific Officer

Innate Pharma

Cedrik Britten

Cedrik Britten

Chief Medical Officer

Immatics

John Carroll

John Carroll

Founder & Editor

Endpoints News

moderator

David Chia

David Chia

Senior Business Development Manager, United Kingdom

Novotech

presenting speaker

10:00 - 10:30 BST
virtual

Fireside Chat with Steve Bates & John Carroll

Steve Bates

Steve Bates

CEO

BIA

John Carroll

John Carroll

Founder & Editor

Endpoints News

11:00 - 12:00 BST
virtual
sponsored by
Catalent

Faster, better, cheaper? What’s next for mRNA?

Some of the leaders in mRNA are driving the next round of innovation in the field. We’ll be talking to some of the top scientists in Europe who are tackling better delivery vehicles, better and faster vaccines with a look at the pipeline of translational therapies that promise to keep the mRNA revolution moving forward.

sponsored by
Catalent
Jean-Francois Toussaint

Jean-Francois Toussaint

Global Head of Research & Development Vaccines

Sanofi

Patrick Baumhof

Patrick Baumhof

Senior Vice President of Technology

CureVac

Dan Peer

Dan Peer

Vice President for Research and Development, and Director of the Laboratory of Precision Nanomedicine

Tel Aviv University

Kenneth Chien

Kenneth Chien

Professor Karolinska Institutet; Co-Founder Moderna and Board member eTheRNA

John Carroll

John Carroll

Founder & Editor

Endpoints News

moderator

Wai Lam W. Ling

Wai Lam W. Ling

VP Scientific Advisory

Catalent

presenting speaker

13:00 - 13:15 BST
live livestream

Welcome remarks

Nooman Haque

Nooman Haque

MD, Life Sciences and Healthcare

Silicon Valley Bank

John Carroll

John Carroll

Founder & Editor

Endpoints News

13:15 - 14:15 BST
live livestream

Surviving a Broken Market

The unprecedented boom that lifted biotech during the pandemic gave way to a brutal bust that eviscerated share prices and dried up generalist interest in the industry. We’ll gather a group of the continent’s top public biotech CEOs to discuss their strategy for weathering the storm while pushing ahead with their most critical R&D plans.

Andrew Hopkins

Andrew Hopkins

Chief Executive Officer & Founder

Exscientia

Kate Bingham

Kate Bingham

Managing Partner

SV Health Investors

Denise Scots‑Knight

Denise Scots‑Knight

Chief Executive Officer

Mereo BioPharma Group, plc

Adrian Rawcliffe

Adrian Rawcliffe

Chief Executive Officer

Adaptimmune

John Carroll

John Carroll

Founder & Editor

Endpoints News

moderator

14:45 - 15:30 BST
live livestream

Fireside Chat with Susan Galbraith and John Carroll

Susan Galbraith

Susan Galbraith

Executive Vice President, Oncology R&D

AstraZeneca

John Carroll

John Carroll

Founder & Editor

Endpoints News

16:00 - 17:00 BST
live livestream
sponsored by
Silicon Valley Bank

Navigating capital headwinds

Private and public markets are riven by turbulence which shows no sign of abating. The biotech sector itself has seen challenges from US healthcare reform to wider political and macroeconomic factors causing stress to all parts of the economy. Finding a clear financial strategy is unnerving and complex and our panellists will do their best to shed light on how to manage in these times.

sponsored by
Silicon Valley Bank
Katya Smirnyagin

Katya Smirnyagin

Senior Partner (Life Sciences)

Oxford Science Enterprises

Maina Bhaman

Maina Bhaman

Partner, Capital Strategy

Sofinnova Partners

Jonathan Hepple

Jonathan Hepple

Founder Partner

Rosetta Capital Ltd

Nooman Haque

Nooman Haque

MD, Life Sciences and Healthcare

Silicon Valley Bank

moderator

17:00 - 18:00 BST
live

Reception with drinks & hors d'oeuvres

We’ll be ending the event on October 12 with drinks and a mixer on the Silicon Valley Bank balcony overlooking London. Endpoints Editor John Carroll and Silicon Valley Bank’s Nooman Haque will be on hand for direct discussions and a chance to catch up on you and your companies. This is always the most fun we have at this event, and one we look forward to eagerly.

Register for virtual panels & livestream

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please contact our support team.